Canaccord Genuity Raised Price target on Aerie Pharma (AERI) Following Rocket 2 Data
Tweet Send to a Friend
Canaccord Genuity reiterated a Buy rating on Aerie Pharma (NASDAQ: AERI), and raised the price target to $44.00 (from $40.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
